Richard Fleming – Event 2021 – Parts 1-7 (Notes)
This is what I’m watching today (Wed 23rd June, 2021).
I’ll remove this message when I’ve finished all parts.
(Videos are still being slowly-uploaded
You are all involved in the largest experimental study ever in the history of mankind; either in the experimental or control group. (02)
This is a slice through tissue of a coronavirus, anyone telling you ‘they don’t exist’ needs to look at this. Anyone who tells you ‘we don’t have the genetic sequence’, we do. This is what it looks like, these are spike proteins. (05) And this is a cryo-electron micrograph. (06)
The unique thing about this virus is its spike protein. This is the spike protein. It looks like a tree. It is a molecule. The 3 unique regions above are not found in other CoronaViruses.
Spike protein has at least 3 unusual inserts not found together in related natural CVs:
1. HIV Pseudovirus glycoprotein 120
2. PRRA insert furin cleavage site
3. Prion-like domain at RBS (ACE2 receptor binding site)
They used PCR-testing to prove that’s what they had.
They followed Kary Mullis (1944 – 2019) who got the patent for PCR-test, and what Dr Mullis said, is you stop PCR-testing at 20 cycles. and that’s what his patent said, because anything more causes you to artificially induce things that really aren’t real and at 20 cycles you will find anything that’s really there. Dr Mullis was the last person to take on Anthony Fauci. He died from pneumonia in a few months before the SARS-CoV-2 outbreak in 2019 at age 74.
Federal monies that have invested into this research spans decades. (19)
NIH put grant-money into this patent, so they have certain rights in the invention.
NIH has patent rights for the insertion of the enzymes related to the furin cleavage site.
Insertions: We’ve got HIV gp 120 and PRRA, which produces a prion-like domain.
We’re supposed to do animal-research before we do people. Here’s what we know from animal studies:
In ‘humanized-mice’ (mice that we gave Ace-2 receptors to so we can work with them), 98% of them were dead after 2 weeks. When we looked at them, we saw this under the microscope (video does not pan to indicate where he’s pointing). This looks like a sponge, and it’s in the brain, that the general public calls “Mad Cow disease”. (34)
In Monkeys, in 5-6 week, a part of their brain was infected with spike proteins. And when we looked at their brains, we saw inflammatory cells and lewy bodies (Alzheimer’s & other neurological diseases). Animals didn’t have this before they were exposed. This is the result of the spike protein crossing the blood-brain barrier & getting to its target. (35)
Symptoms of SARS-CoV-2 vs COVID-19
Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19:
- Fever or chills
- Shortness of breath or difficulty breathing
- Muscle or body aches
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
How do you know when the infection becomes the disease “COVID-19”.
Emergency warning signs for COVID-19:
If someone is showing any of these signs, seek
emergency medical care immediately:
- Trouble breathing
- Persistent pain or pressure in the chest
- New confusion
- Inability to wake or stay awake
- Pale, gray, or blue-coloured skin, lips, or nail beds, depending on skin tone
COVID-19 is an InflammoThrombotic disease that occurs in people who already have InflammoThrombotic diseases. Obesity, Heart Disease, Diabetes, High blood-pressure, Cancer, Vascular disease. These diseases already have blood clotting & inflammation associated with them. These pre-disposed people without treatment, will die.
The blood clots come from your legs and other places, this is a deep venous thrombosis, which is our term for a blood clot in the veins, deep in the body, usually in the calves or the thighs. It forms there, and when it loosens up, it’s a ‘moving blood-clot’.
How is SARS-CoV-2 Transmitted?
Person-to-Person via respiratory or gastrointestinal passages, or by injecting it.
Patients of COVID-19 are not being treated because the doctors are told there are no treatments and that if you treat, there will be repercussions. (39)
Treatment needs to focus on:
- Virus attachment & Entry into the cell.
- Virus replication once inside the cell.
- Reducing Inflammation & Blood Clotting (ITR) associated with the T-Cell (Innate) response to the virus.
- Reducing Inflammation & Blood Clotting (ITR) associated with the B-cell (Delayed Humoral) response to the virus.
- As well as Medicines that improve airflow & reduce blood clotting.
Deaths are all the result of the federal government telling people there is no treatment, and not allowing doctors to practice medicine, and controlling the way in which that practice of medicine is being conducted.
You have to address the air-flow and the blood-clotting independently. (40)
Quantitatively Measured Treatments with 1800 infected people across 7 countries. Focusing on 10 different treatment options in 52 treatment combinations. (Cuba, India, Philippines, South Africa, Belgium, Germany, Brazil)
Successful treatment outcomes were defined using the quantitative measurements of FMTVDM with a reduction of > 25, or a level of < 150, Ferritin levels < 270 ng/ml for men and < 160 ng/ml for women, and an IL-6 level of < 5 pg/ml.
|(1) 100% Effective [Treatment Regimen 4]|
• Primaquine 200 mg by mouth on day 1.
• Clindamycin 150 mg by mouth every 6-hours for 7-days.
• Hydroxychloroquine 200 mg by mouth every 8-hours for 10-days.
|(3) 74.2% Effective [Treatment Regimen 1]|
• Hydroxychloroquine 200 mg by mouth every 8-hours for 10-days.
• Azithromycin 500 mg by mouth on day 1, then 250 mg by mouth on days 2 through 5.
|(2) 97.9% Effective [Treatment Regimen 3]|
• Hydroxychloroquine 200 mg by mouth every 8-hours for 10-days.
• Clindamycin 150 mg by mouth every 6-hours for 7-days.
|(4) 69.1% Effective [Treatment Regimen 2]|
• Hydroxychloroquine 200 mg by mouth every 8-hours for 10-days.
• Doxycycline 100 mg by mouth every 12-hours for 10-days.
What If The People You Trust Are The People Causing The Problem?
- The same people who helped fund and develop SARS-CoV-2 have also controlled how doctors, nurses, & other health care providers are treating patients.
- These people – it turns out – are the same people who helped fund and develop the drug vaccines.
Unlike the other Infectious Agents, Viruses do NOT have a Nucleus or Ribosomes. They can’t independently reproduce, or make their own energy (mitochondria/chloroplasts).
Viruses are essentially ‘genetic material’ wrapped up in a ball, that require other cells to do their work for them. So treating them with drugs that we would normally use for bacteria, fungi, yeast, or parasites doesn’t work. You have to target ‘what they do’. What they are good at, is infecting cells and using the cells they infect to do all they can’t; to make more of themselves.
The focus needs to be what you can do to prevent attachment, the replication, what can you do when the inflammation and blood-clotting affects the ability for the patient to get enough oxygen, the T-cell & B-cell response.
Different drugs target what the virus does.
For example, Hydroxychloroquine inhibits the viral RNA replication, inhibits toll-like receptor 7 (TLR7) to reduce inflammatory response, inhibits glycoprotein IIb/Illa thereby interfering with thrombus formation, inhibits viral attachment at ACE-2 receptor site, reduces the production of pro-inflammatory cytokines, enhances entry of zinc through zinc ionophore, increases cytosol pH to reduce removal of viral envelope required for replication, increases cellular pH decreasing major histocompatibility complex (MHC) viral antigen presentation to B-cells thereby decreasing release of inflammatory cytokines, & enhances production of Type I Interferons.
We have all these drugs that have mechanisms of action that can target the virus, but the government says there’s no treatment available. If you think your doctor is not afraid of the government coming after them, you’re wrong. The premise is that ‘if the government comes after you, you must be the bad guy’. So we have government preventing doctors from using drugs, and we’re left with vaccines. (53)
Do the vaccines prevent you from infection or transmitting it?
// Plays video from Fauci (which I couldn’t find a link to, but it’s in the presentation)
95% chance you will not get symptomatic infection… until we prove that the vaccine prevents transmission… people who are vaccinated should wear a mask around those who might be vulnerable to infection.~ Fauci
Vaccines work because they prime your body to be ready when you are infected. Something comes in, it’s an antigen; a vaccine – a protein that is foreign to your body, comes in, gets broken down in the cells, gets presented to the MHC-I, where the T-cells will recognize it, and they get activated and they look for other cells that are infected that also have this antigen presented.
They release chemicals, cause damage, cause inflammation, and cause blood-clotting. To “kill” the invading organism. Except in this case there’s no actual invading organism. You injected it into yourself.
The pieces that go out, whether that’s the whole virus or the vaccine, and in this case, the spike protein, come back into other cells, those cells will pick them up with MHC-II (3-5 days), a little bit later on (7-10 days), Beta cells recognize MHC-II, and make antibodies. So anything outside in the bloodstream, the antibodies will go and attack, and take them out of commission so they can’t attach to you and cause harm. That’s what vaccines do.
They cause you to make T-cell & B-cell responses, that you will form memory cells to. We do not want T-cell and antibodies floating around your bloodstream forever.
Nothing you have seen in the emergency-use authorization documents for these experimental vaccines, show any of this data, which ought to be the data that the FDA would want to show that it’s working. It’s a vaccine that should produce T-cell and B-cell responses.
How do scientists actually know if a drug or biological (vaccine) agent works?
Before we begin testing people, we begin with pre-clinical testing.
1.) When possible computer modelling and work on isolated cell cultures and tissue.
2.) Animal testing has been an obligatory step before testing on humans. There are a wide-variety of ‘rules’ when animal testing.
There are 3 fundamental principles followed to protect the well-being of the research animals:
- Reduce the number of animals to a min.
- Reduce or minimize the harm & injury to the animal
- Replace animal experiments with nonanimal studies wherever possible.
Once you know enough from the animal studies to determine RISKS & BENEFITS, THEN human research trials are considered.
Phases of Clinical Trials (57)
Phase one: Is it Safe?
Phase two: Is it Effective?
Phase three: Is it Better?
(Typically 10 years)
- Phase I – Determine Safety.
- Phase II (aka Exploratory Trials) – If a Safe Dose is Found – Does the Drug Work?
- Phase III – How does the drug compare with that already used for the problem? (This phase of research occurs when there is compelling evidence of efficacy & safety).
Demonstrate the drug is Effective & Safe in a larger number of patients in the target group (the people the drug is intended to treat). Monitor side effects & risks. Test different doses and different ways of giving the drug. Can the drug be used at different stages of the disease being treated – early, late .…Provide sufficient information about the drug for marketing approval -> FDA.
- Phase IV – Post Marketing Surveillance Studies (The long-term effect of the drug or treatment & other impact or use of the drug.)
Emergency Use Authorization for Vaccines to Prevent COVID-19 (FDA)
The Emergency Use Authorization document. Issued in Oct 2020. Non-binding recommendation. Doesn’t place the FDA or the public under any obligation.
These are the Emergency Use Authorization requirements:
These are critical. If any of these 4 get knocked-out, EUA (Emergency Use Authorization) dies. The problem is, there ARE adequate treatments.
By “definition”, the EUA doesn’t exist. The PCR-Tests – Gone. The Emergency-Vaccines – Gone.
If we don’t learn from history, we are destined to repeat it.
Plays an old (1979) segment from CBS ’60 Minutes’ on the swine flu (also known as H1N1) & the vaccine that was developed to stop the pandemic.
Go to FlemingMethod.com
In the Menu, Click on More to find Documents
You will find 60+ papers detailing much of what the presentation was about, & a lot of things that weren’t, including information that relates to the argument of whether you want to be having antibodies.
Last year, the Osaka Japanese group published a paper talking about Antibody Dependent Enhancement (preprint). This Antibody Dependent Enhancement attaches to part of the spike protein, and when it does that, it opens up the spike protein to make it more infective. They discovered that part of the reason why people in hospitals were not doing better even when they made antibodies, is because the antibodies they made might have too much antibody to where it exacerbated the infection.
There are a lot of terms used regarding Vaccine Efficacy. You should know 3 terms.
The relative risk reduction. This is what you’ve heard so much about, the 95%, the 94%, the 65%. This is how many people got diagnosed with covid in the vaccinated group vs people who got diagnosed in the non-vaccinated group.
There is a more important term for you to understand, and that’s absolute risk reduction: a comparison of those groups that says ‘what’s the “REAL” difference between those groups?”
Then there’s the number needed to vaccinate, which is ‘how many people would you have to vaccinate, to try to reduce one person from being diagnosed with covid.
This means the # of people who got vaccinated that were diagnosed with covid. This is one example from Pfizer. Compared to the people who did not get vaccinated who got diagnosed with covid. When you do the math, it gives you 0.05. 1 minus that number tells you vaccine-efficacy. Multiplied by 100 gives you percent.
So how did they decide who made the diagnose of covid? You had to have 2 things, you had to have a positive PCR-test, and you had to have a set of symptoms.
Pfizer – same symptoms you would get with ‘any‘ infection – viral, bacterial, fungal, tuberculosis, etc.
Moderna – same problem, same issue. They’re what you’d normally have for symptoms – ache’s and pains, muscle discomfort, cough, runny nose, that type of thing.
J&J – Belgium company which btw, Belgium pulled this from the market.
Let’s look at the Emergency Use documents.
- 8 people who got vaccinated were diagnosed with covid. (66)
- 162 in non-vaccinated group were diagnosed with covid. (67)
- Comes up with 95% efficacy
- But you’re not asking how often you’re going to get covid.
- Your question is will it prevent me from getting diagnosed with covid?
- Will it prevent me from dying with covid?
- So let’s look at the data. Their data, not mine.
- If we ask for confirmed covid cases, you’ll see that in the vaccinated group for Pfizer there was 17,411 people
- 8 people diagnosed with covid.
- Which leaves you with 17,403 who did not develop covid.
- Non-vaccinated, there were 17,511
- 162 were diagnosed with covid.
- Which leaves you with 17,349 who did not develop covid.
If you’re a scientist like me, you analyze the data and ask “is there any real difference between those 2 groups?”
It turns out, when you do that, there’s not. It’s not statistically different.
- What was the absolute risk reduction?
- 0.93 minus the difference in those vaccinated, gives you an absolute risk reduction of 0.88%
- If you ask if it cut down the risk of death, here’s the data:
- Pfizer had 2 deaths, Non-vaccinated had 4 deaths
- No statistically significant difference in the numbers of deaths, and they represent what is seen in the general population.
- Pfizer = No statistically difference whether you get vaccinated or not. No significant changes in deaths.
These are the EUA-presented to the FDA that resulted in them being granted Emergency Use Authorization clearance.
- COVID diagnosis = 11 people vaccinated group, 185 people in non-vaccinated group gives you 94% efficacy.
- Vaccinated group 13934 people. 11 ended up with covid. Leaves you with 13923 who didn’t get covid.
- Non-Vaccinated group 13983 people. 185 ended up with covid. Leaves you with 13698 who didn’t get covid.
- Is there differences between those groups? No there isn’t.
- The absolute risk reduction 1.33% minus 0.08% = 1.25%
- Deaths = 6 in the moderna group
- Deaths = 7 in the non-vaccinated group
- No statistical difference.
- And it’s what you’d expect to see in the general population.
Janssen (J&J / Johnson & Johnson)
- They use: Moderate to Severe as definition. 14 days & 28 days.
- At 14 days, 176 in vaccinated group, 513 in non-vaccinated group. Efficacy 66%
- At 28 days, 114 in vaccinated group, 326 in non-vaccinated group. Efficacy 65%
- Now let’s look at the likelihood that you won’t develop covid.
- 14 days – 21636 in the vaccinated group. 21575 in non-vaccinated group.
- 21460 did not develop covid in vaccinated group.
- 21575 did not develop covid in non-vaccinated group.
- There is a statistically significant difference of 0.05%
- Absolute Risk Reduction at 14 days. 2.38% minus 0.81% = 1.57%
- The 14 day data is what they got EUA approval with (not the 28 day data)
- Let’s look at the data 2 weeks later.
- 28 days – 21424 – 114 diagnosed with covid = 21310 vaccinated group
- 28 days – 21199 – 326 diagnosed with covid = 20873 non-vaccinated group
- 2 weeks later. No longer statistically significant.
- Absolute Risk Reduction = 1.54% minus 0.53% = 1.01%
- Everytime you do a research study in more than one site, you have everybody making their decisions non-centrally.
- But everything goes to a central lab, where the people in charge make a decision. Yes or No.
- Not centrally confirmed numbers (Table 14) vs centrally confirmed numbers (Table 15)
- Go to centrally confirmed and eliminate “Mild” (because noone dies from “mild covid”)
- And you get 32-42% drop in the covid cases when you use the centrally-confirmed lab results.
- Which was not used to determine whether the FDA should authorize EUA.
- 5 Deaths in Janssen group. Of these Five: 2 of them were ‘unknown’
- 20 Deaths in non-vaccinated group.
(Conference gets a Skype call-in from Dr. Yan so presentation is halted to hear from her.)
Waiting for Part 9 to be uploaded to continue this section.
Part 9 – Hasn’t been uploaded yet
Based Upon the FDA (EUA) Documents:
- There is no statistical reduction in COVID rates.
- There is no statistical reduction in COVID death rates.
- There is an unacceptable VAERS death and adverse event rates. (88)
- The vaccine Absolute Risk Reduction (ARR) rate for developing COVID is really only 0.8 to 1.3%. Not the 67 to 95% you’ve been lead to believe.
The FDA, the Federal Government and the Media failed to do their job. They failed to ask the Scientific Questions that should have been asked.
|02↩||Event 2021 – Part 1 – Rumble|
|03↩, 07↩, 09↩||Event 2021 – Part 1 – Rumble|
|04↩||Cryo-Electron Tomography of SARS-CoV-2 showing spike proteins|
October 9, 2020
|05↩||Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome|
|06↩||Spike protein of the new corona virus is more flexible than expected|
|08↩||Evidence that SARS-CoV-2 is not naturally evolved|
July 1, 2020
|10↩||Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus|
|11↩||Preparation of a Chimeric Armored RNA as a Versatile Calibrator for Multiple Virus Assays – Boyd Yount, Kristopher M. Curtis, Elizabeth A. Fritz, Lisa E. Hensley, Peter B. Jahrling, Erik Prentice, Mark R. Denison, Thomas W. Geisbert, Ralph S. BaricProceedings of the National Academy of Sciences Oct 2003, 100 (22) 12995-13000; DOI: 10.1073/pnas.1735582100|
|12↩||Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates – Published 28 Sept 2020 & also included in Clinical Infectious Diseases, Volume 72, Issue 11, 1 June 2021, Page e921, https://doi.org/10.1093/cid/ciaa1491|
|13↩||Interpreting the COVID-19 Test Results – Chang, Min Cheol MD; Hur, Jian MD; Park, Donghwi MD Interpreting the COVID-19 Test Results, American Journal of Physical Medicine & Rehabilitation: July 2020 – Volume 99 – Issue 7 – p 583-585 doi: 10.1097/PHM.0000000000001471|
|14↩||Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples – Jared Bullard, Kerry Dust, Duane Funk, James E Strong, David Alexander, Lauren Garnett, Carl Boodman, Alexander Bello, Adam Hedley, Zachary Schiffman, Kaylie Doan, Nathalie Bastien, Yan Li, Paul G Van Caeseele, Guillaume Poliquin, Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples, Clinical Infectious Diseases, Volume 71, Issue 10, 15 November 2020, Pages 2663–2666, https://doi.org/10.1093/cid/ciaa638|
|15↩, 19↩, 28↩, 31↩, 37↩||Event 2021 – Part 2 – Rumble|
|16↩||Deleted Wuhan Databases.|
February 23, 2021
|17↩||SARS-CoV-2 Is an Unrestricted Bioweapon.|
Released April 24, 2021
|18↩||SARS-CoV-2 – A Scientific Discussion of Lab Origin.|
March 25, 2021
|20↩||Patent: Methods And Compositions For Chimeric Coronavirus Spike Proteins|
|21↩||Methods And Compositions For Chimeric Coronavirus Spike Proteins|
|22↩||Covid-19, Sars And Bats Coronaviruses Genomes Peculiar Homologous Rna Sequences – International Journal of Research|
|23↩||COVID-19, SARS and Bats Coronaviruses Genomes Unexpected Exogenous RNA Sequences – ResearchGate – Perez, jean-claude & Montagnier, Luc. (2020). COVID-19, SARS and Bats Coronaviruses Genomes Unexpected Exogenous RNA Sequences.|
|24↩||Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route – Yan, Li-Meng, Kang, Shu, Guan, Jie, & Hu, Shanchang. (2020, September 14). Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route. Zenodo. http://doi.org/10.5281/zenodo.4028830|
|25↩||A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells – Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020 May 21;78(4):779-784.e5. doi: 10.1016/j.molcel.2020.04.022. Epub 2020 May 1. PMID: 32362314; PMCID: PMC7194065.|
|26↩||TMPRSS2 and Furin Both Essential for SARS-CoV-2 Infection of Cells. July 23, 2020|
|27↩||Origins of SARS and PRRA. August 12, 2020|
|29↩||Patent for PRRA Furin Cleavage Site with Certain Patent Rights Owned by U.S. Governmnent (NIH).|
May 29, 2007
|30↩||Insertion of furin protease cleavage sites in membrane proteins and uses thereof – Google Patents|
|32↩||SARS-CoV-2 Spike protein crosses the blood brain barrier in mice study|
December 16, 2020
|33↩||RNA can Behave like Prions. July 1, 2020|
|34↩||Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 expression – Mariano Carossino, Paige Montanaro, Aoife O’Connell, Devin Kenney, Hans Gertje, Kyle A. Grosz, Susanna A. Kurnick, Markus Bosmann, Mohsan Saeed, Udeni B. R. Balasuriya, Florian Douam, Nicholas A. Crossland|
bioRxiv 2021.01.13.425144; doi: https://doi.org/10.1101/2021.01.13.425144
|35↩||SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques – Ingrid H.C.H.M. Philippens, Kinga P. Böszörményi, Jacqueline A. Wubben, Zahra C. Fagrouch, Nikki van Driel, Amber Q. Mayenburg, Diana Lozovagia, Eva Roos, Bernadette Schurink, Marianna Bugiani, Ronald E. Bontrop, Jinte Middeldorp, Willy M. Bogers, Lioe-Fee de Geus-Oei, Jan A.M. Langermans, Marieke A. Stammes, Babs E. Verstrepen, Ernst J. Verschoor – bioRxiv 2021.02.23.432474; doi: https://doi.org/10.1101/2021.02.23.432474|
|36↩||Tetz, G.; Tetz, V. SARS-CoV-2 Prion-Like Domains in Spike Proteins Enable Higher Affinity to ACE2. Preprints 2020, 2020030422 (doi: 10.20944/preprints202003.0422.v1). – Preprint|
|38↩||Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020 Aug 18;173(4):268-277. doi: 10.7326/M20-2003. Epub 2020 May 6. PMID: 32374815; PMCID: PMC7240772.|
|39↩, 40↩, 41↩, 42↩, 50↩||Event 2021 – Part 3 – Rumble|
|43↩||FMTVDM Quantitative Nuclear Imaging finds Three Treatments for SARS-CoV-2|
|44↩||FMTVDM Quantitative Nuclear Imaging finds Three Treatments for SARS-CoV-2|
|45↩||COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study|
|46↩||Alexander, Paul & Armstrong, Robin & Fareed, George & Gill, Kulvinder & Lotus, John & Oskoui, Ramin & Podromomos, Chad & Fonseca, Silvia & Tenenbaum, Howard & Wax, Craig & McCullough, Peter. (2021). Early Multidrug Outpatient Treatment of SARS-CoV-2 Infection (COVID-19) and Reduced Mortality Among Nursing Home Residents. 10.1101/2021.01.28.21250706.|
|47↩||Early Treatment Saves Lives|
|48↩||Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19|
|49↩||Atalla, E.; Zhang, R.; Shehadeh, F.; Mylona, E.K.; Tsikala-Vafea, M.; Kalagara, S.; Henseler, L.; Chan, P.A.; Mylonakis, E. Clinical Presentation, Course, and Risk Factors Associated with Mortality in a Severe Outbreak of COVID-19 in Rhode Island, USA, April–June 2020. Pathogens 2021, 10, 8. https://doi.org/10.3390/pathogens10010008|
|51↩, 52↩, 53↩, 54↩, 55↩, 56↩||Event 2021 – Part 4 – Rumble|
|57↩||Event 2021 – Part 5 – Rumble|
|58↩||Emergency Use Authorization for Vaccines to Prevent COVID – FDA|
|59↩, 61↩, 62↩, 63↩, 64↩, 66↩||Event 2021 – Part 6 – Rumble|
|60↩||An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies Yafei Liu, Wai Tuck Soh, Asa Tada, Akemi Arakawa, Sumiko Matsuoka, Emi E. Nakayama, Songling Li, Chikako Ono, Shiho Torii, Kazuki Kishida, Hui Jin, Wataru Nakai, Noriko Arase, Atsushi Nakagawa, Yasuhiro Shindo, Masako Kohyama, Hironori Nakagami, Keisuke Tomii, Koichiro Ohmura, Shiro Ohshima, Masato Okada, Yoshiharu Matsuura, Daron M. Standley, Tatsuo Shioda, Hisashi Arase bioRxiv 2020.12.18.423358; doi: https://doi.org/10.1101/2020.12.18.423358|
|65↩, 70↩, 72↩||Pfizer EUA document|
|67↩, 69↩, 71↩, 73↩, 75↩, 77↩, 79↩, 81↩, 82↩, 83↩, 84↩, 85↩||Event 2021 – Part 7 – Rumble|
|68↩||Event 2021 – Part 7 – Rumble|
|74↩, 76↩, 78↩||Moderna EUA Document|
|80↩||Janssen (Johnson & Johnson) EUA Document.|
February 26, 2021
|86↩||The Vaccine Adverse Event Reporting System (VAERS)|
|87↩||Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room [published online ahead of print, 2021 Apr 20]. Lancet Microbe. 2021;10.1016/S2666-5247(21)00069-0. doi:10.1016/S2666-5247(21)00069-0|
|88↩||The Vaccine Adverse Event Reporting System (VAERS)|